BR112023026976A2 - Inibidores do inflamassoma nlrp3 - Google Patents

Inibidores do inflamassoma nlrp3

Info

Publication number
BR112023026976A2
BR112023026976A2 BR112023026976A BR112023026976A BR112023026976A2 BR 112023026976 A2 BR112023026976 A2 BR 112023026976A2 BR 112023026976 A BR112023026976 A BR 112023026976A BR 112023026976 A BR112023026976 A BR 112023026976A BR 112023026976 A2 BR112023026976 A2 BR 112023026976A2
Authority
BR
Brazil
Prior art keywords
compounds
present
inhibitors
nlrp3 inflammasome
relates
Prior art date
Application number
BR112023026976A
Other languages
English (en)
Portuguese (pt)
Inventor
Giulia Bergonzini
Henrik Gradén
Hiroshi Sugama
Anders Mikael Johansson Lars
Takehiko Matsumura
Original Assignee
Astrazeneca Ab
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Mitsubishi Tanabe Pharma Corp filed Critical Astrazeneca Ab
Publication of BR112023026976A2 publication Critical patent/BR112023026976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112023026976A 2021-07-02 2022-07-01 Inibidores do inflamassoma nlrp3 BR112023026976A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163217970P 2021-07-02 2021-07-02
PCT/EP2022/068292 WO2023275366A1 (en) 2021-07-02 2022-07-01 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
BR112023026976A2 true BR112023026976A2 (pt) 2024-03-12

Family

ID=82611090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026976A BR112023026976A2 (pt) 2021-07-02 2022-07-01 Inibidores do inflamassoma nlrp3

Country Status (31)

Country Link
US (2) US11970463B2 (cg-RX-API-DMAC7.html)
EP (2) EP4628490A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024523623A (cg-RX-API-DMAC7.html)
KR (1) KR20240031343A (cg-RX-API-DMAC7.html)
CN (1) CN117580826A (cg-RX-API-DMAC7.html)
AR (1) AR126351A1 (cg-RX-API-DMAC7.html)
AU (2) AU2022304254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023026976A2 (cg-RX-API-DMAC7.html)
CA (1) CA3224513A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003939A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000565A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240038A (cg-RX-API-DMAC7.html)
DK (1) DK4363406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000002A (cg-RX-API-DMAC7.html)
EC (1) ECSP24008862A (cg-RX-API-DMAC7.html)
ES (1) ES3054790T3 (cg-RX-API-DMAC7.html)
FI (1) FI4363406T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251513T1 (cg-RX-API-DMAC7.html)
IL (1) IL309680A (cg-RX-API-DMAC7.html)
LT (1) LT4363406T (cg-RX-API-DMAC7.html)
MA (1) MA65277B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000234A (cg-RX-API-DMAC7.html)
PE (1) PE20250122A1 (cg-RX-API-DMAC7.html)
PL (1) PL4363406T3 (cg-RX-API-DMAC7.html)
PT (1) PT4363406T (cg-RX-API-DMAC7.html)
RS (1) RS67463B1 (cg-RX-API-DMAC7.html)
SI (1) SI4363406T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500441T1 (cg-RX-API-DMAC7.html)
TW (1) TW202321201A (cg-RX-API-DMAC7.html)
UY (1) UY39839A (cg-RX-API-DMAC7.html)
WO (1) WO2023275366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250162767A (ko) * 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
KR20250074627A (ko) * 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026006510A1 (en) * 2024-06-26 2026-01-02 Virginia Commonwealth University Compounds as nlrp3 inhibitors, and compositions and uses thereof
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
CN111315733A (zh) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Nlrp3モジュレーター

Also Published As

Publication number Publication date
JP2024523623A (ja) 2024-06-28
UY39839A (es) 2023-01-31
PL4363406T3 (pl) 2026-01-05
CL2023003939A1 (es) 2024-08-30
ES3054790T3 (en) 2026-02-06
KR20240031343A (ko) 2024-03-07
FI4363406T3 (fi) 2025-12-02
EP4363406B1 (en) 2025-09-10
AU2022304254B2 (en) 2025-06-12
HRP20251513T1 (hr) 2026-01-02
EP4628490A2 (en) 2025-10-08
US12503445B2 (en) 2025-12-23
ECSP24008862A (es) 2024-03-01
SI4363406T1 (sl) 2026-01-30
MA65277B1 (fr) 2025-12-31
AU2022304254A1 (en) 2024-02-08
EP4363406A1 (en) 2024-05-08
AR126351A1 (es) 2023-10-11
AU2025223957A1 (en) 2025-09-18
DK4363406T3 (da) 2025-12-01
EP4628490A3 (en) 2025-12-03
CO2024000565A2 (es) 2024-04-18
US20230110122A1 (en) 2023-04-13
IL309680A (en) 2024-02-01
US11970463B2 (en) 2024-04-30
CR20240038A (es) 2024-05-24
CN117580826A (zh) 2024-02-20
US20240383862A1 (en) 2024-11-21
WO2023275366A1 (en) 2023-01-05
TW202321201A (zh) 2023-06-01
SMT202500441T1 (it) 2026-01-12
RS67463B1 (sr) 2025-12-31
CA3224513A1 (en) 2023-01-05
DOP2024000002A (es) 2024-05-15
PT4363406T (pt) 2025-12-15
MX2024000234A (es) 2024-04-16
LT4363406T (lt) 2025-12-29
PE20250122A1 (es) 2025-01-16

Similar Documents

Publication Publication Date Title
CO2024000565A2 (es) Inhibidores del inflamasoma nlrp3
BR112022021735A2 (pt) Compostos úteis para inibir cinase ret
MX2023007192A (es) Inhibidores de prmt5.
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
BR0108613A (pt) Novo uso de derivados de fenilheteroalquiilamina
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BRPI0918602B8 (pt) inibidores da atividade de ssao, seu uso, e formulação farmacêutica
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BR112022006018A2 (pt) Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1
BR0312000A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BR112022018586A2 (pt) Derivados de ácido borônico e usos terapêuticos dos mesmos
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]

Free format text: REFERENTE A 2775 DE 12/03/2024, QUANTO AO ITEM (54)